Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER+/HER2- breast cancer
{{output}}
Background: Patients with advanced estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer commonly develop resistance to treatment with hormone therapy and cyclin-dependent kinases 4/6 (CDK4/6) inhibitors. Responders... ...
